secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001372514-25-000064
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M
--------------------------------------------------------------------------------

- Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.
- KLARITY Phase 2 trial for KIO-104 in retinal inflammation initiated; patent exclusivity extended to 2043.
- ABACUS-2 Phase 2 trial of KIO-301 for retinitis pigmentosa initiated with validated functional vision endpoint.
- Option agreement with Senju for KIO-301 in Asia; potential deal value up to $110M plus royalties; $1.25M option fee received.
- R&D expense $2.6M offset by $1.7M Théa reimbursement; G&A down to $1.4M from $1.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000064/0001372514-25-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000064/kprx-20250808.htm
  HTML page:      https://secwatch.observer/filing/0001372514-25-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer